{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:32:58Z","timestamp":1794583978851,"version":"4.9.1"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005856","name":"NOVA | Faculdade de Ci\u00eancias e Tecnologia, Universidade Nova de Lisboa","doi-asserted-by":"publisher","award":["PTDC\/SAU-SER\/29635\/2017"],"award-info":[{"award-number":["PTDC\/SAU-SER\/29635\/2017"]}],"id":[{"id":"10.13039\/501100005856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005856","name":"NOVA | Faculdade de Ci\u00eancias e Tecnologia, Universidade Nova de Lisboa","doi-asserted-by":"publisher","award":["UIDB\/50026\/2020 and UIDP\/50026\/2020"],"award-info":[{"award-number":["UIDB\/50026\/2020 and UIDP\/50026\/2020"]}],"id":[{"id":"10.13039\/501100005856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI153356"],"award-info":[{"award-number":["R01AI153356"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI063503"],"award-info":[{"award-number":["R01AI063503"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["no. 847507"],"award-info":[{"award-number":["no. 847507"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-022-01172-2","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T12:13:48Z","timestamp":1659442428000},"page":"1127-1140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":478,"title":["COVID-19-associated fungal infections"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-2824","authenticated-orcid":false,"given":"Martin","family":"Hoenigl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danila","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2457-6437","authenticated-orcid":false,"given":"Rosanne","family":"Sprute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6002-5782","authenticated-orcid":false,"given":"Cristina","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7969-2796","authenticated-orcid":false,"given":"Matteo","family":"Oliverio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2986-350X","authenticated-orcid":false,"given":"Gustavo H.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-8530","authenticated-orcid":false,"given":"Ashraf S.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8935-8030","authenticated-orcid":false,"given":"Agostinho","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"1172_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8, 475\u2013481 (2020).","journal-title":"Lancet Respir. Med."},{"key":"1172_CR2","doi-asserted-by":"publisher","unstructured":"Arastehfar, A. et al. COVID-19 associated pulmonary aspergillosis (CAPA)\u2014from immunology to treatment. J. Fungi https:\/\/doi.org\/10.3390\/jof6020091 (2020).","DOI":"10.3390\/jof6020091"},{"key":"1172_CR3","doi-asserted-by":"publisher","unstructured":"Koehler, P. et al. COVID-19 associated pulmonary aspergillosis. Mycoses https:\/\/doi.org\/10.1111\/myc.13096 (2020).","DOI":"10.1111\/myc.13096"},{"key":"1172_CR4","doi-asserted-by":"publisher","unstructured":"Prattes, J. et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients\u2014a multinational observational study by the European Confederation of Medical Mycology. Clin. Microbiol. Infect. https:\/\/doi.org\/10.1016\/j.cmi.2021.08.014 (2021).","DOI":"10.1016\/j.cmi.2021.08.014"},{"key":"1172_CR5","doi-asserted-by":"publisher","unstructured":"Permpalung, N. Coronavirus disease 2019\u2014associated pulmonary aspergillosis in mechanically ventilated patients. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciab223 (2021).","DOI":"10.1093\/cid\/ciab223"},{"key":"1172_CR6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3201\/eid2704.204895","volume":"27","author":"J Salmanton-Garc\u00eda","year":"2021","unstructured":"Salmanton-Garc\u00eda, J. et al. COVID-19-associated pulmonary aspergillosis, March\u2013August 2020. Emerg. Infect. Dis. 27, 1077\u20131086 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"1172_CR7","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.3201\/eid2711.211174","volume":"27","author":"NAF Janssen","year":"2021","unstructured":"Janssen, N. A. F. et al. Multinational observational cohort study of COVID-19-associated pulmonary aspergillosis. Emerg. Infect. Dis. 27, 2892\u20132898 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"1172_CR8","doi-asserted-by":"publisher","unstructured":"White, P. L. et al. A national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa1298 (2020).","DOI":"10.1093\/cid\/ciaa1298"},{"key":"1172_CR9","doi-asserted-by":"publisher","unstructured":"Bartoletti, M. et al. Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: a prospective study. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa1065 (2020).","DOI":"10.1093\/cid\/ciaa1065"},{"key":"1172_CR10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3390\/jof7121067","volume":"7","author":"S Feys","year":"2021","unstructured":"Feys, S. et al. A visual and comprehensive review on COVID-19-associated pulmonary aspergillosis (CAPA). J. Fungi 7, 1067 (2021).","journal-title":"J. Fungi"},{"key":"1172_CR11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2213-2600(21)00442-2","volume":"10","author":"J-P Gangneux","year":"2022","unstructured":"Gangneux, J.-P. et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir. Med. 10, 180\u2013190 (2022).","journal-title":"Lancet Respir. Med."},{"key":"1172_CR12","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.4103\/ijo.IJO_310_21","volume":"69","author":"SA Ravani","year":"2021","unstructured":"Ravani, S. A., Agrawal, G. A., Leuva, P. A., Modi, P. H. & Amin, K. D. Rise of the phoenix: mucormycosis in COVID-19 times. Indian J. Ophthalmol. 69, 1563\u20131568 (2021).","journal-title":"Indian J. Ophthalmol."},{"key":"1172_CR13","doi-asserted-by":"publisher","unstructured":"Raut, A. & Huy, N. T. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? Lancet Respir. Med. https:\/\/doi.org\/10.1016\/S2213-2600(21)00265-4 (2021).","DOI":"10.1016\/S2213-2600(21)00265-4"},{"key":"1172_CR14","doi-asserted-by":"publisher","unstructured":"Hoenigl, M. et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe https:\/\/doi.org\/10.1016\/S2666-5247(21)00237-8 (2022).","DOI":"10.1016\/S2666-5247(21)00237-8"},{"key":"1172_CR15","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.3201\/eid2709.210934","volume":"27","author":"A Patel","year":"2021","unstructured":"Patel, A. et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg. Infect. Dis. 27, 2349\u20132359 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"1172_CR16","doi-asserted-by":"publisher","unstructured":"Rudramurthy, S. M. et al. ECMM\/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses https:\/\/doi.org\/10.1111\/myc.13335 (2021).","DOI":"10.1111\/myc.13335"},{"key":"1172_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507\u2013513 (2020).","journal-title":"Lancet"},{"key":"1172_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.15585\/mmwr.mm7002e3","volume":"70","author":"C Prestel","year":"2021","unstructured":"Prestel, C. et al. Candida auris outbreak in a COVID-19 specialty care unit\u2014Florida, July\u2013August 2020. MMWR Morb. Mortal. Wkly Rep. 70, 56\u201357 (2021).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"1172_CR19","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cmi.2020.12.030","volume":"27","author":"H Villanueva-Lozano","year":"2021","unstructured":"Villanueva-Lozano, H. et al. Outbreak of Candida auris infection in a COVID-19 hospital in Mexico. Clin. Microbiol. Infect. 27, 813\u2013816 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"1172_CR20","doi-asserted-by":"publisher","unstructured":"Larkin, E. et al. The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02396-16 (2017).","DOI":"10.1128\/aac.02396-16"},{"key":"1172_CR21","doi-asserted-by":"publisher","unstructured":"Koehler, P. et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(20)30847-1 (2020).","DOI":"10.1016\/S1473-3099(20)30847-1"},{"key":"1172_CR22","doi-asserted-by":"publisher","unstructured":"Autier, B. et al. Aspergillus lateral flow assay with digital reader for the diagnosis of COVID-19 associated pulmonary aspergillosis (CAPA): a multicenter study. J. Clin. Microbiol. https:\/\/doi.org\/10.1128\/jcm.01689-21 (2021).","DOI":"10.1128\/jcm.01689-21"},{"key":"1172_CR23","doi-asserted-by":"publisher","unstructured":"Prattes, J., Wauters, J., Giacobbe, D. R., Lagrou, K. & Hoenigl, M. Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry. Intensive Care Med. https:\/\/doi.org\/10.1007\/s00134-021-06471-6 (2021).","DOI":"10.1007\/s00134-021-06471-6"},{"key":"1172_CR24","doi-asserted-by":"publisher","first-page":"100115","DOI":"10.1016\/j.simyco.2021.100115","volume":"100","author":"A Arastehfar","year":"2021","unstructured":"Arastehfar, A. et al. Aspergillus fumigatus and aspergillosis: from basics to clinics. Stud. Mycol. 100, 100115 (2021).","journal-title":"Stud. Mycol."},{"key":"1172_CR25","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1182\/blood-2011-04-351601","volume":"119","author":"A Bergeron","year":"2012","unstructured":"Bergeron, A. et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood 119, 1831\u20131837 (2012).","journal-title":"Blood"},{"key":"1172_CR26","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/mmy\/myv034","volume":"53","author":"R Petraitiene","year":"2015","unstructured":"Petraitiene, R., Petraitis, V., Bacher, J. D., Finkelman, M. A. & Walsh, T. J. Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1\u21923)-\u03b2-D-glucan in experimental invasive pulmonary aspergillosis. Med. Mycol. 53, 558\u2013568 (2015).","journal-title":"Med. Mycol."},{"key":"1172_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","volume":"70","author":"C Kosmidis","year":"2015","unstructured":"Kosmidis, C. & Denning, D. W. The clinical spectrum of pulmonary aspergillosis. Thorax 70, 270\u2013277 (2015).","journal-title":"Thorax"},{"key":"1172_CR28","doi-asserted-by":"publisher","unstructured":"Erg\u00fcn, M. et al. Aspergillus test profiles and mortality in critically-ill COVID-19 patients. J. Clin. Microbiol., https:\/\/doi.org\/10.1128\/jcm.01229-21 (2021).","DOI":"10.1128\/jcm.01229-21"},{"key":"1172_CR29","doi-asserted-by":"publisher","unstructured":"Delli\u00e8re, S. et al. Combination of mycological criteria: a better surrogate to identify COVID-19-associated pulmonary aspergillosis patients and evaluate prognosis?. J. Clin. Microbiol., https:\/\/doi.org\/10.1128\/jcm.02169-21 (2022).","DOI":"10.1128\/jcm.02169-21"},{"key":"1172_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/myc.13183","volume":"64","author":"P Koehler","year":"2021","unstructured":"Koehler, P., Cornely, O. A. & Kochanek, M. Bronchoscopy safety precautions for diagnosing COVID-19 associated pulmonary aspergillosis\u2014a simulation study. Mycoses 64, 55\u201359 (2021).","journal-title":"Mycoses"},{"key":"1172_CR31","doi-asserted-by":"publisher","unstructured":"Fekkar, A. et al. COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it? Clin. Microbiol. Infect. https:\/\/doi.org\/10.1016\/j.cmi.2021.06.025 (2021).","DOI":"10.1016\/j.cmi.2021.06.025"},{"key":"1172_CR32","doi-asserted-by":"publisher","unstructured":"Egger, M., Bussini, L., Hoenigl, M. & Bartoletti, M. Prevalence of COVID-19-associated pulmonary aspergillosis: critical review and conclusions. J. Fungi https:\/\/doi.org\/10.3390\/jof8040390 (2022).","DOI":"10.3390\/jof8040390"},{"key":"1172_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","volume":"186","author":"SI Blot","year":"2012","unstructured":"Blot, S. I. et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am. J. Respir. Crit. Care Med. 186, 56\u201364 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1172_CR34","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","volume":"46","author":"PE Verweij","year":"2020","unstructured":"Verweij, P. E. et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 46, 1524\u20131535 (2020).","journal-title":"Intensive Care Med."},{"key":"1172_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-020-00686-4","volume":"10","author":"L Rutsaert","year":"2020","unstructured":"Rutsaert, L. et al. COVID-19-associated invasive pulmonary aspergillosis. Ann. Intensive Care 10, 71 (2020).","journal-title":"Ann. Intensive Care"},{"key":"1172_CR36","doi-asserted-by":"publisher","unstructured":"Lamoth, F., Glampedakis, E., Boillat-Blanco, N., Oddo, M. & Pagani, J.-L. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clin. Microbiol. Infect. https:\/\/doi.org\/10.1016\/j.cmi.2020.07.010 (2020).","DOI":"10.1016\/j.cmi.2020.07.010"},{"key":"1172_CR37","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2213-2600(20)30237-X","volume":"8","author":"A Alanio","year":"2020","unstructured":"Alanio, A., Delli\u00e8re, S., Fodil, S., Bretagne, S. & M\u00e9garbane, B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir. Med. 8, e48\u2013e49 (2020).","journal-title":"Lancet Respir. Med."},{"key":"1172_CR38","doi-asserted-by":"publisher","unstructured":"Gangneux, J.-P. et al. Is the COVID-19 pandemic a good time to include Aspergillus molecular detection to categorize aspergillosis in ICU patients? A monocentric experience. J. Fungi https:\/\/doi.org\/10.3390\/jof6030105 (2020).","DOI":"10.3390\/jof6030105"},{"key":"1172_CR39","doi-asserted-by":"publisher","unstructured":"Prattes, J., Koehler, P. & Hoenigl, M. COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges. Intensive Care Med. https:\/\/doi.org\/10.1007\/s00134-021-06510-2 (2021).","DOI":"10.1007\/s00134-021-06510-2"},{"key":"1172_CR40","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s00134-021-06603-y","volume":"48","author":"MC Soriano","year":"2022","unstructured":"Soriano, M. C., Narv\u00e1ez-Ch\u00e1vez, G., L\u00f3pez-Olivencia, M., Fort\u00fan, J. & de Pablo, R. Inhaled amphotericin B lipid complex for prophylaxis against COVID-19-associated invasive pulmonary aspergillosis. Intensive Care Med. 48, 360\u2013361 (2022).","journal-title":"Intensive Care Med."},{"key":"1172_CR41","doi-asserted-by":"publisher","first-page":"e0229821","DOI":"10.1128\/jcm.02298-21","volume":"60","author":"DR Giacobbe","year":"2022","unstructured":"Giacobbe, D. R. et al. Prognostic impact of bronchoalveolar lavage fluid galactomannan and Aspergillus culture results on survival in COVID-19 intensive care unit patients: a post hoc analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-associated pulmonary aspergillosis study. J. Clin. Microbiol. 60, e0229821 (2022).","journal-title":"J. Clin. Microbiol."},{"key":"1172_CR42","doi-asserted-by":"publisher","unstructured":"Egger, M., Hoenigl, M., Thompson, G. R. III, Carvalho, A. & Jenks, J. D. Let\u2019s talk about sex characteristics\u2014as a risk factor for invasive fungal diseases. Mycoses https:\/\/doi.org\/10.1111\/myc.13449 (2022).","DOI":"10.1111\/myc.13449"},{"key":"1172_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/myc.12243","volume":"57","author":"A Chakrabarti","year":"2014","unstructured":"Chakrabarti, A. & Singh, R. Mucormycosis in India: unique features. Mycoses 57, 85\u201390 (2014).","journal-title":"Mycoses"},{"key":"1172_CR44","doi-asserted-by":"publisher","unstructured":"Prakash, H. & Chakrabarti, A. Epidemiology of mucormycosis in India. Microorganisms https:\/\/doi.org\/10.3390\/microorganisms9030523 (2021).","DOI":"10.3390\/microorganisms9030523"},{"key":"1172_CR45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/mmy\/myz031","volume":"58","author":"H Prakash","year":"2020","unstructured":"Prakash, H. et al. An aero mycological analysis of Mucormycetes in indoor and outdoor environments of northern India. Med. Mycol. 58, 118\u2013123 (2020).","journal-title":"Med. Mycol."},{"key":"1172_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","volume":"25","author":"W Jeong","year":"2019","unstructured":"Jeong, W. et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin. Microbiol. Infect. 25, 26\u201334 (2019).","journal-title":"Clin. Microbiol. Infect."},{"key":"1172_CR47","doi-asserted-by":"publisher","unstructured":"Seidel, D. Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals. Mycoses https:\/\/doi.org\/10.1111\/myc.13379 (2022).","DOI":"10.1111\/myc.13379"},{"key":"1172_CR48","doi-asserted-by":"publisher","unstructured":"Cornely, O. A. et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/s1473-3099(19)30312-3 (2019).","DOI":"10.1016\/s1473-3099(19)30312-3"},{"key":"1172_CR49","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.4103\/ijo.IJO_1565_21","volume":"69","author":"M Sen","year":"2021","unstructured":"Sen, M. et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India\u2014collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), report 1. Indian J. Ophthalmol. 69, 1670\u20131692 (2021).","journal-title":"Indian J. Ophthalmol."},{"key":"1172_CR50","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/myc.13332","volume":"64","author":"B Kayaaslan","year":"2021","unstructured":"Kayaaslan, B. et al. Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients. Mycoses 64, 1083\u20131091 (2021).","journal-title":"Mycoses"},{"key":"1172_CR51","doi-asserted-by":"publisher","unstructured":"Riche, C. V. W., Cassol, R. & Pasqualotto, A. C. Is the frequency of candidemia increasing in COVID-19 patients receiving corticosteroids? J. Fungi https:\/\/doi.org\/10.3390\/jof6040286 (2020).","DOI":"10.3390\/jof6040286"},{"key":"1172_CR52","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/cid\/ciab562","volume":"74","author":"EE Seagle","year":"2022","unstructured":"Seagle, E. E. et al. The landscape of candidemia during the coronavirus disease 2019 (COVID-19) pandemic. Clin. Infect. Dis. 74, 802\u2013811 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"1172_CR53","doi-asserted-by":"publisher","unstructured":"Arastehfar, A. et al. COVID-19-associated candidiasis (CAC): an underestimated complication in the absence of immunological predispositions? J. Fungi https:\/\/doi.org\/10.3390\/jof6040211 (2020).","DOI":"10.3390\/jof6040211"},{"key":"1172_CR54","doi-asserted-by":"publisher","unstructured":"Jeffery-Smith, A. et al. Candida auris: a review of the literature. Clin. Microbiol. Rev. https:\/\/doi.org\/10.1128\/cmr.00029-17 (2017).","DOI":"10.1128\/cmr.00029-17"},{"key":"1172_CR55","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jgar.2020.06.003","volume":"22","author":"A Chowdhary","year":"2020","unstructured":"Chowdhary, A. & Sharma, A. The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemic. J. Glob. Antimicrob. Resist. 22, 175\u2013176 (2020).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"1172_CR56","doi-asserted-by":"publisher","first-page":"e00901","DOI":"10.1002\/mbo3.901","volume":"8","author":"J Osei Sekyere","year":"2019","unstructured":"Osei Sekyere, J. Candida auris: a systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiologyopen 8, e00901 (2019).","journal-title":"Microbiologyopen"},{"key":"1172_CR57","doi-asserted-by":"publisher","unstructured":"Moin, S. et al. C. auris and non-C. auris candidemia in hospitalized adult and pediatric COVID-19 patients; single center data from Pakistan. Med. Mycol. https:\/\/doi.org\/10.1093\/mmy\/myab057 (2021).","DOI":"10.1093\/mmy\/myab057"},{"key":"1172_CR58","doi-asserted-by":"publisher","unstructured":"Rajni, E. et al. A high frequency of Candida auris blood stream infections in coronavirus disease 2019 patients admitted to intensive care units, Northwestern India: a case control study. Open Forum Infect. Dis. https:\/\/doi.org\/10.1093\/ofid\/ofab452 (2021).","DOI":"10.1093\/ofid\/ofab452"},{"key":"1172_CR59","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/jcph.1787","volume":"61","author":"Y Mo","year":"2021","unstructured":"Mo, Y. et al. Treatment with tocilizumab for patients with COVID-19 infections: a case-series study. J. Clin. Pharmacol. 61, 406\u2013411 (2021).","journal-title":"J. Clin. Pharmacol."},{"key":"1172_CR60","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ajic.2021.11.015","volume":"50","author":"M Alsuhaibani","year":"2022","unstructured":"Alsuhaibani, M. et al. Impact of COVID-19 on an infection prevention and control program, Iowa 2020\u20132021. Am. J. Infect. Control 50, 277\u2013282 (2022).","journal-title":"Am. J. Infect. Control"},{"key":"1172_CR61","doi-asserted-by":"publisher","unstructured":"Magnasco, L. et al. Spread of carbapenem-resistant Gram-negatives and Candida auris during the COVID-19 pandemic in critically ill patients: one step back in antimicrobial stewardship? Microorganisms https:\/\/doi.org\/10.3390\/microorganisms9010095 (2021).","DOI":"10.3390\/microorganisms9010095"},{"key":"1172_CR62","doi-asserted-by":"publisher","unstructured":"Mulet Bayona, J. V. Impact of the SARS-CoV-2 pandemic in candidaemia, invasive aspergillosis and antifungal consumption in a tertiary hospital. J. Fungi https:\/\/doi.org\/10.3390\/jof7060440 (2021).","DOI":"10.3390\/jof7060440"},{"key":"1172_CR63","doi-asserted-by":"publisher","first-page":"e0009421","DOI":"10.1128\/CMR.00094-21","volume":"35","author":"F Salazar","year":"2022","unstructured":"Salazar, F., Bignell, E., Brown, G. D., Cook, P. C. & Warris, A. Pathogenesis of respiratory viral and fungal coinfections. Clin. Microbiol. Rev. 35, e0009421 (2022).","journal-title":"Clin. Microbiol. Rev."},{"key":"1172_CR64","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"1172_CR65","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41587-020-0602-4","volume":"38","author":"RL Chua","year":"2020","unstructured":"Chua, R. L. et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat. Biotechnol. 38, 970\u2013979 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1172_CR66","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.chom.2020.02.006","volume":"27","author":"DL Wiesner","year":"2020","unstructured":"Wiesner, D. L. et al. Club cell TRPV4 serves as a damage sensor driving lung allergic inflammation. Cell Host Microbe 27, 614\u2013628.e6 (2020).","journal-title":"Cell Host Microbe"},{"key":"1172_CR67","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1038\/s41564-019-0558-7","volume":"4","author":"CH Kowalski","year":"2019","unstructured":"Kowalski, C. H. et al. Fungal biofilm morphology impacts hypoxia fitness and disease progression. Nat. Microbiol. 4, 2430\u20132441 (2019).","journal-title":"Nat. Microbiol."},{"key":"1172_CR68","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1182\/blood-2009-07-231209","volume":"114","author":"R Ben-Ami","year":"2009","unstructured":"Ben-Ami, R., Lewis, R. E., Leventakos, K. & Kontoyiannis, D. P. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood 114, 5393\u20135399 (2009).","journal-title":"Blood"},{"key":"1172_CR69","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41564-020-00837-0","volume":"6","author":"SSM Soliman","year":"2021","unstructured":"Soliman, S. S. M. et al. Mucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis. Nat. Microbiol. 6, 313\u2013326 (2021).","journal-title":"Nat. Microbiol."},{"key":"1172_CR70","doi-asserted-by":"publisher","first-page":"101695","DOI":"10.1016\/j.jbc.2022.101695","volume":"298","author":"JP Robles","year":"2022","unstructured":"Robles, J. P. et al. The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin \u03b15\u03b21 and NF-\u03baB signaling. J. Biol. Chem. 298, 101695 (2022).","journal-title":"J. Biol. Chem."},{"key":"1172_CR71","doi-asserted-by":"publisher","first-page":"16211","DOI":"10.1038\/nmicrobiol.2016.211","volume":"2","author":"H Liu","year":"2016","unstructured":"Liu, H. et al. Aspergillus fumigatus CalA binds to integrin \u03b15\u03b21 and mediates host cell invasion. Nat. Microbiol. 2, 16211 (2016).","journal-title":"Nat. Microbiol."},{"key":"1172_CR72","doi-asserted-by":"publisher","unstructured":"Alqarihi, A. et al. GRP78 and integrins play different roles in host cell invasion during mucormycosis. Mbio https:\/\/doi.org\/10.1128\/mBio.01087-20 (2020).","DOI":"10.1128\/mBio.01087-20"},{"key":"1172_CR73","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.4049\/jimmunol.1200524","volume":"189","author":"S Jawhara","year":"2012","unstructured":"Jawhara, S. et al. Integrin \u03b1X\u03b22 is a leukocyte receptor for Candida albicans and is essential for protection against fungal infections. J. Immunol. 189, 2468\u20132477 (2012).","journal-title":"J. Immunol."},{"key":"1172_CR74","doi-asserted-by":"publisher","first-page":"e00252-16","DOI":"10.1128\/mBio.00252-16","volume":"7","author":"MJ Lee","year":"2016","unstructured":"Lee, M. J. et al. Deacetylation of fungal exopolysaccharide mediates adhesion and biofilm formation. Mbio 7, e00252-16 (2016).","journal-title":"Mbio"},{"key":"1172_CR75","doi-asserted-by":"publisher","unstructured":"Bedi, S. & Ono, A. Friend or foe: the role of the cytoskeleton in influenza A virus assembly. Viruses https:\/\/doi.org\/10.3390\/v11010046 (2019).","DOI":"10.3390\/v11010046"},{"key":"1172_CR76","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.micinf.2014.03.001","volume":"16","author":"X Jia","year":"2014","unstructured":"Jia, X. et al. Gliotoxin promotes Aspergillus fumigatus internalization into type II human pneumocyte A549 cells by inducing host phospholipase D activation. Microbes Infect. 16, 491\u2013501 (2014).","journal-title":"Microbes Infect."},{"key":"1172_CR77","doi-asserted-by":"publisher","first-page":"e02242","DOI":"10.1128\/mBio.02242-15","volume":"7","author":"D Schlam","year":"2016","unstructured":"Schlam, D. et al. Gliotoxin suppresses macrophage immune function by subverting phosphatidylinositol 3,4,5-trisphosphate homeostasis. Mbio 7, e02242 (2016).","journal-title":"Mbio"},{"key":"1172_CR78","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1164\/rccm.202008-3265OC","volume":"203","author":"DA Dorward","year":"2021","unstructured":"Dorward, D. A. et al. Tissue-specific immunopathology in fatal COVID-19. Am. J. Respir. Crit. Care Med. 203, 192\u2013201 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1172_CR79","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fimmu.2012.00286","volume":"3","author":"C Cunha","year":"2012","unstructured":"Cunha, C., Carvalho, A., Esposito, A., Bistoni, F. & Romani, L. DAMP signaling in fungal infections and diseases. Front. Immunol. 3, 286 (2012).","journal-title":"Front. Immunol."},{"key":"1172_CR80","doi-asserted-by":"publisher","first-page":"e27962","DOI":"10.1371\/journal.pone.0027962","volume":"6","author":"C Cunha","year":"2011","unstructured":"Cunha, C. et al. Genetically-determined hyperfunction of the S100B\/RAGE axis is a risk factor for aspergillosis in stem cell transplant recipients. PLoS ONE 6, e27962 (2011).","journal-title":"PLoS ONE"},{"key":"1172_CR81","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fcvm.2020.00037","volume":"7","author":"L Ega\u00f1a-Gorro\u00f1o","year":"2020","unstructured":"Ega\u00f1a-Gorro\u00f1o, L. et al. Receptor for advanced glycation end products (RAGE) and mechanisms and therapeutic opportunities in diabetes and cardiovascular disease: insights from human subjects and animal models. Front. Cardiovasc. Med. 7, 37 (2020).","journal-title":"Front. Cardiovasc. Med."},{"key":"1172_CR82","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2665-9913(20)30343-X","volume":"2","author":"BJ Webb","year":"2020","unstructured":"Webb, B. J. et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol. 2, e754\u2013e763 (2020).","journal-title":"Lancet Rheumatol."},{"key":"1172_CR83","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1749-6632.2012.06754.x","volume":"1273","author":"A Carvalho","year":"2012","unstructured":"Carvalho, A. et al. Inflammation in aspergillosis: the good, the bad, and the therapeutic. Ann. N. Y. Acad. Sci. 1273, 52\u201359 (2012).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1172_CR84","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.cell.2020.08.001","volume":"182","author":"J Schulte-Schrepping","year":"2020","unstructured":"Schulte-Schrepping, J. et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell 182, 1419\u20131440.e23 (2020).","journal-title":"Cell"},{"key":"1172_CR85","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.immuni.2021.03.005","volume":"54","author":"PA Szabo","year":"2021","unstructured":"Szabo, P. A. et al. Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. Immunity 54, 797\u2013814.e6 (2021).","journal-title":"Immunity"},{"key":"1172_CR86","doi-asserted-by":"publisher","unstructured":"Kvedaraite, E. et al. Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity. Proc. Natl Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.2018587118 (2021).","DOI":"10.1073\/pnas.2018587118"},{"key":"1172_CR87","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jinf.2019.04.002","volume":"78","author":"M Stanzani","year":"2019","unstructured":"Stanzani, M., Vianelli, N., Cavo, M., Kontoyiannis, D. P. & Lewis, R. E. Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. J. Infect. 78, 484\u2013490 (2019).","journal-title":"J. Infect."},{"key":"1172_CR88","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1182\/blood-2011-07-366526","volume":"118","author":"L Potenza","year":"2011","unstructured":"Potenza, L. et al. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood 118, 5416\u20135419 (2011).","journal-title":"Blood"},{"key":"1172_CR89","doi-asserted-by":"publisher","first-page":"742","DOI":"10.14336\/AD.2020.0619","volume":"11","author":"MD Schwartz","year":"2020","unstructured":"Schwartz, M. D., Emerson, S. G., Punt, J. & Goff, W. D. Decreased na\u00efve T-cell production leading to cytokine storm as cause of increased COVID-19 severity with comorbidities. Aging Dis. 11, 742\u2013745 (2020).","journal-title":"Aging Dis."},{"key":"1172_CR90","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718\u2013724 (2020).","journal-title":"Science"},{"key":"1172_CR91","doi-asserted-by":"publisher","unstructured":"Hsu, J. C., Laurent-Rolle, M., Pawlak, J. B., Wilen, C. B. & Cresswell, P. Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. Proc. Natl Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.2101161118 (2021).","DOI":"10.1073\/pnas.2101161118"},{"key":"1172_CR92","doi-asserted-by":"publisher","unstructured":"Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science https:\/\/doi.org\/10.1126\/science.abd4585 (2020).","DOI":"10.1126\/science.abd4585"},{"key":"1172_CR93","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1365-2567.2010.03302.x","volume":"131","author":"V Gafa","year":"2010","unstructured":"Gafa, V. et al. Enhancement of anti-Aspergillus T helper type 1 response by interferon-\u03b2-conditioned dendritic cells. Immunology 131, 282\u2013288 (2010).","journal-title":"Immunology"},{"key":"1172_CR94","doi-asserted-by":"publisher","unstructured":"Espinosa, V. et al. Type III interferon is a critical regulator of innate antifungal immunity. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aan5357 (2017).","DOI":"10.1126\/sciimmunol.aan5357"},{"key":"1172_CR95","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.1016\/j.cell.2021.08.016","volume":"184","author":"B Sposito","year":"2021","unstructured":"Sposito, B. et al. The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell 184, 4953\u20134968.e16 (2021).","journal-title":"Cell"},{"key":"1172_CR96","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1126\/science.abc3545","volume":"369","author":"A Broggi","year":"2020","unstructured":"Broggi, A. et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science 369, 706\u2013712 (2020).","journal-title":"Science"},{"key":"1172_CR97","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.abc2061","volume":"369","author":"J Major","year":"2020","unstructured":"Major, J. et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science 369, 712\u2013717 (2020).","journal-title":"Science"},{"key":"1172_CR98","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1126\/science.1093616","volume":"303","author":"SS Diebold","year":"2004","unstructured":"Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S. & Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529\u20131531 (2004).","journal-title":"Science"},{"key":"1172_CR99","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/jama.2020.13719","volume":"324","author":"CI van der Made","year":"2020","unstructured":"van der Made, C. I. et al. Presence of genetic variants among young men with severe COVID-19. JAMA 324, 663\u2013673 (2020).","journal-title":"JAMA"},{"key":"1172_CR100","doi-asserted-by":"publisher","unstructured":"Xu, B., Luo, Q., Gong, Y., Li, J. & Cao, J. TLR7 expression aggravates invasive pulmonary aspergillosis by suppressing anti-Aspergillus immunity of macrophages. Infect. Immun. https:\/\/doi.org\/10.1128\/iai.00019-21 (2021).","DOI":"10.1128\/iai.00019-21"},{"key":"1172_CR101","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/infdis\/jiab065","volume":"223","author":"NAF Janssen","year":"2021","unstructured":"Janssen, N. A. F. et al. Dysregulated innate and adaptive immune responses discriminate disease severity in COVID-19. J. Infect. Dis. 223, 1322\u20131333 (2021).","journal-title":"J. Infect. Dis."},{"key":"1172_CR102","doi-asserted-by":"publisher","first-page":"e1000549","DOI":"10.1371\/journal.pgen.1000549","volume":"5","author":"L-J Ma","year":"2009","unstructured":"Ma, L.-J. et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet. 5, e1000549 (2009).","journal-title":"PLoS Genet."},{"key":"1172_CR103","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2958.2010.07234.x","volume":"77","author":"AS Ibrahim","year":"2010","unstructured":"Ibrahim, A. S. et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol. Microbiol. 77, 587\u2013604 (2010).","journal-title":"Mol. Microbiol."},{"key":"1172_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12218","volume":"7","author":"MC Chibucos","year":"2016","unstructured":"Chibucos, M. C. et al. An integrated genomic and transcriptomic survey of mucormycosis-causing fungi. Nat. Commun. 7, 12218 (2016).","journal-title":"Nat. Commun."},{"key":"1172_CR105","doi-asserted-by":"publisher","first-page":"e1004496","DOI":"10.1371\/journal.pgen.1004496","volume":"10","author":"VU Schwartze","year":"2014","unstructured":"Schwartze, V. U. et al. Gene expansion shapes genome architecture in the human pathogen Lichtheimia corymbifera: an evolutionary genomics analysis in the ancient terrestrial Mucorales (Mucoromycotina). PLoS Genet. 10, e1004496 (2014).","journal-title":"PLoS Genet."},{"key":"1172_CR106","doi-asserted-by":"publisher","first-page":"e1003625","DOI":"10.1371\/journal.ppat.1003625","volume":"9","author":"SC Lee","year":"2013","unstructured":"Lee, S. C., Li, A., Calo, S. & Heitman, J. Calcineurin plays key roles in the dimorphic transition and virulence of the human pathogenic zygomycete Mucor circinelloides. PLoS Pathog. 9, e1003625 (2013).","journal-title":"PLoS Pathog."},{"key":"1172_CR107","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1172\/JCI71349","volume":"124","author":"T Gebremariam","year":"2014","unstructured":"Gebremariam, T. et al. CotH3 mediates fungal invasion of host cells during mucormycosis. J. Clin. Invest. 124, 237\u2013250 (2014).","journal-title":"J. Clin. Invest."},{"key":"1172_CR108","doi-asserted-by":"publisher","unstructured":"Liu, M. et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI42164 (2010).","DOI":"10.1172\/JCI42164"},{"key":"1172_CR109","doi-asserted-by":"publisher","unstructured":"Gebremariam, T. et al. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI82744 (2016).","DOI":"10.1172\/JCI82744"},{"key":"1172_CR110","doi-asserted-by":"publisher","first-page":"118781","DOI":"10.1016\/j.lfs.2020.118781","volume":"265","author":"R Sabirli","year":"2021","unstructured":"Sabirli, R., Koseler, A., Goren, T., Turkcuer, I. & Kurt, O. High GRP78 levels in Covid-19 infection: a case-control study. Life Sci. 265, 118781 (2021).","journal-title":"Life Sci."},{"key":"1172_CR111","doi-asserted-by":"publisher","first-page":"100759","DOI":"10.1016\/j.jbc.2021.100759","volume":"296","author":"AJ Carlos","year":"2021","unstructured":"Carlos, A. J. et al. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection. J. Biol. Chem. 296, 100759 (2021).","journal-title":"J. Biol. Chem."},{"key":"1172_CR112","doi-asserted-by":"publisher","unstructured":"Venkataraman, T., Coleman, C. M. & Frieman, M. B. Overactive epidermal growth factor receptor signaling leads to increased fibrosis after severe acute respiratory syndrome coronavirus infection. J. Virol. https:\/\/doi.org\/10.1128\/JVI.00182-17 (2017).","DOI":"10.1128\/JVI.00182-17"},{"key":"1172_CR113","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.molcel.2020.08.006","volume":"80","author":"K Klann","year":"2020","unstructured":"Klann, K. et al. Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication. Mol. Cell 80, 164\u2013174.e4 (2020).","journal-title":"Mol. Cell"},{"key":"1172_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05820-2","volume":"9","author":"AM Andrianaki","year":"2018","unstructured":"Andrianaki, A. M. et al. Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species. Nat. Commun. 9, 3333 (2018).","journal-title":"Nat. Commun."},{"key":"1172_CR115","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.mib.2011.07.004","volume":"14","author":"AS Ibrahim","year":"2011","unstructured":"Ibrahim, A. S. Host cell invasion in mucormycosis: role of iron. Curr. Opin. Microbiol. 14, 406\u2013411 (2011).","journal-title":"Curr. Opin. Microbiol."},{"key":"1172_CR116","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/s-0039-3401992","volume":"41","author":"G Reid","year":"2020","unstructured":"Reid, G., Lynch, J. P. 3rd, Fishbein, M. C. & Clark, N. M.Mucormycosis. Semin. Respir. Crit. Care Med. 41, 99\u2013114 (2020).","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"1172_CR117","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","volume":"362","author":"MS Lionakis","year":"2003","unstructured":"Lionakis, M. S. & Kontoyiannis, D. P. Glucocorticoids and invasive fungal infections. Lancet 362, 1828\u20131838 (2003).","journal-title":"Lancet"},{"key":"1172_CR118","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.cmet.2021.05.013","volume":"33","author":"C-T Wu","year":"2021","unstructured":"Wu, C.-T. et al. SARS-CoV-2 infects human pancreatic \u03b2 cells and elicits \u03b2 cell impairment. Cell Metab. 33, 1565\u20131576.e5 (2021).","journal-title":"Cell Metab."},{"key":"1172_CR119","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s42255-021-00347-1","volume":"3","author":"JA M\u00fcller","year":"2021","unstructured":"M\u00fcller, J. A. et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat. Metab. 3, 149\u2013165 (2021).","journal-title":"Nat. Metab."},{"key":"1172_CR120","doi-asserted-by":"publisher","first-page":"108291","DOI":"10.1016\/j.diabres.2020.108291","volume":"166","author":"N Goldman","year":"2020","unstructured":"Goldman, N., Fink, D., Cai, J., Lee, Y.-N. & Davies, Z. High prevalence of COVID-19-associated diabetic ketoacidosis in UK secondary care. Diabetes Res. Clin. Pract. 166, 108291 (2020).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1172_CR121","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","volume":"27","author":"EJ Giamarellos-Bourboulis","year":"2020","unstructured":"Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27, 992\u20131000.e3 (2020).","journal-title":"Cell Host Microbe"},{"key":"1172_CR122","doi-asserted-by":"publisher","first-page":"640644","DOI":"10.3389\/fimmu.2021.640644","volume":"12","author":"D Moser","year":"2021","unstructured":"Moser, D. et al. COVID-19 impairs immune response to Candida albicans. Front. Immunol. 12, 640644 (2021).","journal-title":"Front. Immunol."},{"key":"1172_CR123","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.4049\/jimmunol.1002599","volume":"186","author":"C Bourgeois","year":"2011","unstructured":"Bourgeois, C. et al. Conventional dendritic cells mount a type I IFN response against Candida spp. requiring novel phagosomal TLR7-mediated IFN-\u03b2 signaling. J. Immunol. 186, 3104\u20133112 (2011).","journal-title":"J. Immunol."},{"key":"1172_CR124","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/eji.201242532","volume":"42","author":"C Biondo","year":"2012","unstructured":"Biondo, C. et al. Recognition of fungal RNA by TLR7 has a nonredundant role in host defense against experimental candidiasis. Eur. J. Immunol. 42, 2632\u20132643 (2012).","journal-title":"Eur. J. Immunol."},{"key":"1172_CR125","doi-asserted-by":"publisher","unstructured":"Armstrong-James, D. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis (CAPA). Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.02554-2020 (2020).","DOI":"10.1183\/13993003.02554-2020"},{"key":"1172_CR126","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1093\/cid\/ciaa1177","volume":"72","author":"CMP Jeronimo","year":"2021","unstructured":"Jeronimo, C. M. P. et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin. Infect. Dis. 72, e373\u2013e381 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"1172_CR127","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMc2108482","volume":"385","author":"MJ Brown","year":"2021","unstructured":"Brown, M. J., Alazawi, W. & Kanoni, S. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N. Engl. J. Med. 385, 1147 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1172_CR128","doi-asserted-by":"publisher","first-page":"583897","DOI":"10.3389\/fmed.2020.583897","volume":"7","author":"LM Kimmig","year":"2020","unstructured":"Kimmig, L. M. et al. IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. Front. Med. 7, 583897 (2020).","journal-title":"Front. Med."},{"key":"1172_CR129","doi-asserted-by":"publisher","unstructured":"Calder\u00f3n-Parra, J. et al. COVID-19-associated pulmonary aspergillosis (CAPA): risk factors and development of a predictive score for critically ill COVID-19 patients. Mycoses https:\/\/doi.org\/10.1111\/myc.13434 (2022).","DOI":"10.1111\/myc.13434"},{"key":"1172_CR130","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.chom.2021.06.002","volume":"29","author":"T Akoumianaki","year":"2021","unstructured":"Akoumianaki, T. et al. Uncoupling of IL-6 signaling and LC3-associated phagocytosis drives immunoparalysis during sepsis. Cell Host Microbe 29, 1277\u20131293.e6 (2021).","journal-title":"Cell Host Microbe"},{"key":"1172_CR131","doi-asserted-by":"publisher","unstructured":"Rodrigues, T. S. et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20201707 (2021).","DOI":"10.1084\/jem.20201707"},{"key":"1172_CR132","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-020-2996-z","volume":"588","author":"B Briard","year":"2020","unstructured":"Briard, B. et al. Galactosaminogalactan activates the inflammasome to provide host protection. Nature 588, 688\u2013692 (2020).","journal-title":"Nature"},{"key":"1172_CR133","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.chom.2015.01.006","volume":"17","author":"R Karki","year":"2015","unstructured":"Karki, R. et al. Concerted activation of the AIM2 and NLRP3 inflammasomes orchestrates host protection against Aspergillus infection. Cell Host Microbe 17, 357\u2013368 (2015).","journal-title":"Cell Host Microbe"},{"key":"1172_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10791","volume":"7","author":"RG Iannitti","year":"2016","unstructured":"Iannitti, R. G. et al. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. Nat. Commun. 7, 10791 (2016).","journal-title":"Nat. Commun."},{"key":"1172_CR135","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1073\/pnas.1322831111","volume":"111","author":"A de Luca","year":"2014","unstructured":"de Luca, A. et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc. Natl Acad. Sci. USA 111, 3526\u20133531 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1172_CR136","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.immuni.2011.02.006","volume":"34","author":"G Guarda","year":"2011","unstructured":"Guarda, G. et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34, 213\u2013223 (2011).","journal-title":"Immunity"},{"key":"1172_CR137","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","volume":"27","author":"E Kyriazopoulou","year":"2021","unstructured":"Kyriazopoulou, E. et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat. Med. 27, 1752\u20131760 (2021).","journal-title":"Nat. Med."},{"key":"1172_CR138","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00134-021-06449-4","volume":"47","author":"PE Verweij","year":"2021","unstructured":"Verweij, P. E. et al. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Med. 47, 819\u2013834 (2021).","journal-title":"Intensive Care Med."},{"key":"1172_CR139","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","volume":"28","author":"FL van de Veerdonk","year":"2022","unstructured":"van de Veerdonk, F. L. et al. A guide to immunotherapy for COVID-19. Nat. Med. 28, 39\u201350 (2022).","journal-title":"Nat. Med."},{"key":"1172_CR140","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/infdis\/jiab044","volume":"224","author":"A Boumaza","year":"2021","unstructured":"Boumaza, A. et al. Monocytes and macrophages, targets of severe acute respiratory syndrome coronavirus 2: the clue for coronavirus disease 2019 immunoparalysis. J. Infect. Dis. 224, 395\u2013406 (2021).","journal-title":"J. Infect. Dis."},{"key":"1172_CR141","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-166","volume":"14","author":"CE Delsing","year":"2014","unstructured":"Delsing, C. E. et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect. Dis. 14, 166 (2014).","journal-title":"BMC Infect. Dis."},{"key":"1172_CR142","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.medj.2021.09.003","volume":"2","author":"A van Laarhoven","year":"2021","unstructured":"van Laarhoven, A. et al. Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: a case series. Med 2, 1163\u20131170.e2 (2021).","journal-title":"Med"},{"key":"1172_CR143","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00134-021-06377-3","volume":"47","author":"LS Nguyen","year":"2021","unstructured":"Nguyen, L. S., Ait Hamou, Z., Gastli, N., Chapuis, N. & P\u00e8ne, F. Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesis. Intensive Care Med. 47, 619\u2013621 (2021).","journal-title":"Intensive Care Med."},{"key":"1172_CR144","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1084\/jem.20050749","volume":"202","author":"A Torosantucci","year":"2005","unstructured":"Torosantucci, A. et al. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202, 597\u2013606 (2005).","journal-title":"J. Exp. Med."},{"key":"1172_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98659-5","volume":"11","author":"T Di Mambro","year":"2021","unstructured":"Di Mambro, T. et al. A new humanized antibody is effective against pathogenic fungi in vitro. Sci. Rep. 11, 19500 (2021).","journal-title":"Sci. Rep."},{"key":"1172_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07738-1","volume":"9","author":"FM Rudkin","year":"2018","unstructured":"Rudkin, F. M. et al. Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis. Nat. Commun. 9, 5288 (2018).","journal-title":"Nat. Commun."},{"key":"1172_CR147","doi-asserted-by":"publisher","first-page":"eaaw1327","DOI":"10.1126\/sciadv.aaw1327","volume":"5","author":"T Gebremariam","year":"2019","unstructured":"Gebremariam, T. et al. Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis. Sci. Adv. 5, eaaw1327 (2019).","journal-title":"Sci. Adv."},{"issue":"Suppl. 1","key":"1172_CR148","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1093\/ofid\/ofab466.119","volume":"8","author":"Y Gu","year":"2021","unstructured":"Gu, Y. et al. Humanized antibody targeting the CotH invasins is protective against murine mucormycosis. Open Forum Infect. Dis. 8 (Suppl. 1), S71\u2013S72 (2021).","journal-title":"Open Forum Infect. Dis."},{"key":"1172_CR149","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.mimet.2009.05.002","volume":"78","author":"DA Coleman","year":"2009","unstructured":"Coleman, D. A. et al. Monoclonal antibodies specific for Candida albicans Als3 that immunolabel fungal cells in vitro and in vivo and block adhesion to host surfaces. J. Microbiol. Methods 78, 71\u201378 (2009).","journal-title":"J. Microbiol. Methods"},{"key":"1172_CR150","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1086\/504691","volume":"194","author":"BJ Spellberg","year":"2006","unstructured":"Spellberg, B. J. et al. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J. Infect. Dis. 194, 256\u2013260 (2006).","journal-title":"J. Infect. Dis."},{"key":"1172_CR151","doi-asserted-by":"publisher","first-page":"e1007460","DOI":"10.1371\/journal.ppat.1007460","volume":"15","author":"S Singh","year":"2019","unstructured":"Singh, S. et al. The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection. PLoS Pathog. 15, e1007460 (2019).","journal-title":"PLoS Pathog."},{"key":"1172_CR152","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/myc.12927","volume":"62","author":"EE Tejerina","year":"2019","unstructured":"Tejerina, E. E. et al. Invasive aspergillosis in critically ill patients: an autopsy study. Mycoses 62, 673\u2013679 (2019).","journal-title":"Mycoses"},{"key":"1172_CR153","doi-asserted-by":"publisher","unstructured":"Rocchi, S. et al. Interlaboratory evaluation of Mucorales PCR assays for testing serum specimens: a study by the fungal PCR Initiative and the Modimucor study group. Med. Mycol. https:\/\/doi.org\/10.1093\/mmy\/myaa036 (2020).","DOI":"10.1093\/mmy\/myaa036"},{"key":"1172_CR154","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jinf.2020.05.051","volume":"81","author":"H Guegan","year":"2020","unstructured":"Guegan, H. et al. Evaluation of MucorGenius\u00ae Mucorales PCR assay for the diagnosis of pulmonary mucormycosis. J. Infect. 81, 311\u2013317 (2020).","journal-title":"J. Infect."},{"key":"1172_CR155","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/mmy\/myz101","volume":"58","author":"C Zurl","year":"2020","unstructured":"Zurl, C. et al. T2Candida magnetic resonance in patients with invasive candidiasis: strengths and limitations. Med. Mycol. 58, 632\u2013638 (2020).","journal-title":"Med. Mycol."},{"key":"1172_CR156","doi-asserted-by":"publisher","first-page":"e0021522","DOI":"10.1128\/jcm.00215-22","volume":"60","author":"M Egger","year":"2022","unstructured":"Egger, M. et al. Performance of the Euroimmun Aspergillus antigen ELISA for the diagnosis of invasive pulmonary aspergillosis in bronchoalveolar lavage fluid. J. Clin. Microbiol. 60, e0021522 (2022).","journal-title":"J. Clin. Microbiol."},{"key":"1172_CR157","doi-asserted-by":"publisher","unstructured":"Driemeyer, C. The current state of clinical mycology in Eastern and South-Eastern Europe. Med. Mycol. https:\/\/doi.org\/10.1093\/mmy\/myac017 (2022).","DOI":"10.1093\/mmy\/myac017"},{"key":"1172_CR158","doi-asserted-by":"publisher","unstructured":"Hoenigl, M. et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs https:\/\/doi.org\/10.1007\/s40265-021-01611-0 (2021).","DOI":"10.1007\/s40265-021-01611-0"},{"key":"1172_CR159","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03753-9","volume":"25","author":"S Hatzl","year":"2021","unstructured":"Hatzl, S. et al. Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study. Crit. Care 25, 335 (2021).","journal-title":"Crit. Care"},{"key":"1172_CR160","doi-asserted-by":"publisher","unstructured":"Vanderbeke, L. et al. Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Med. https:\/\/doi.org\/10.1007\/s00134-021-06431-0 (2021).","DOI":"10.1007\/s00134-021-06431-0"},{"key":"1172_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-01259-8","volume":"20","author":"EE Hammond","year":"2020","unstructured":"Hammond, E. E., McDonald, C. S., Vestbo, J. & Denning, D. W. The global impact of Aspergillus infection on COPD. BMC Pulm. Med. 20, 241 (2020).","journal-title":"BMC Pulm. Med."},{"key":"1172_CR162","doi-asserted-by":"publisher","first-page":"e0168921","DOI":"10.1128\/JCM.01689-21","volume":"60","author":"B Autier","year":"2022","unstructured":"Autier, B. et al. Aspergillus lateral flow assay with digital reader for the diagnosis of COVID-19-associated pulmonary aspergillosis (CAPA): a multicenter study. J. Clin. Microbiol. 60, e0168921 (2022).","journal-title":"J. Clin. Microbiol."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01172-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01172-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01172-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T09:53:11Z","timestamp":1669283591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01172-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":162,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1038\/s41564-022-01172-2","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]},"assertion":[{"value":"18 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H. has received funding from the NIH, Astellas Pharma, Pfizer, Gilead Sciences, MSD, F2G, Euroimmun and SCYNEXIS. A.S.I. received funding from Astellas Pharma, Gilead Sciences and Pfizer and owns shares in Vitalex Biosciences, a start-up company that is developing immunotherapies and diagnostics for mucormycosis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}